ADD A CATEGORY
JAN 24, 2013 - Benzinga
A Must Read - Share
Pfizer (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) 8 mg once daily in patients with overactive bladder (OAB) compared to Toviaz 4 mg once daily or placebo met its primary endpoint.
Hey you have no friends!!! Get to work and start inviting friends to help build your Comunitee. Click Here to invite friends.
© 2011 Comunitee, Inc.